NCT06738303View on ClinicalTrials.gov

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 14, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Metastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Cabazitaxel and carboplatin

Given IV

DRUG

Lu-PSMA-617

Given IV

Trial Locations (1)

44106

RECRUITING

Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER